

**IN THE SPECIFICATION:**

**At page 5**, please amend lines 4-6, and lines 8-9, by deleting reference to ATCC, as indicated in the following paragraph:

--In one embodiment, the inhibitory signal-generating pharmaceutical composition's agent can be an anti-MAFA antibody. The anti-MAFA antibody can be an antibody that specifically binds to human MAFA. The anti-MAFA antibody can have the same antigen binding specificity as an antibody produced by a hybridoma designated as 7B5 (~~ATCC~~), or, the anti-MAFA antibody can be produced by a hybridoma designated as 7B5 (~~ATCC~~). In alternative embodiments, the anti-MAFA antibody is an antibody that specifically binds to human MAFA, the anti-MAFA antibody has the same antigen binding specificity as an antibody produced by a hybridoma designated as 1F10 (~~ATCC~~), and, the anti-MAFA antibody can be produced by a hybridoma designated as 1F10 (~~ATCC~~).--

**At page 7**, please amend lines 19-20, and lines 22-23, by deleting reference to ATCC, as indicated in the following paragraph:

--In one embodiment, the inhibited the anti-MAFA antibody is an antibody that specifically binds to human MAFA. In alternative embodiments, the anti-MAFA antibody has the same antigen binding specificity as an antibody produced by a hybridoma designated as 7B5 (~~ATCC~~); the anti-MAFA antibody is produced by a hybridoma designated as 7B5 (~~ATCC~~); the anti-MAFA antibody is an antibody that specifically binds to human MAFA, and the anti-MAFA antibody has the same antigen binding specificity as an antibody produced by a hybridoma designated as 1F10 (~~ATCC~~); and, the anti-MAFA antibody is produced by a hybridoma designated as 1F10 (~~ATCC~~).--